|
|
Article: Halozyme Signs Baxter To Enhanze SC Marketing Deal.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Six-year-old Halozyme Therapeutics Inc. signed a marketing and distribution agreement with Baxter Healthcare Corp. for Halozyme's recombinant human hyaluronidase enzyme product to be used as a spreading agent.
The San Diego-based biopharmaceutical company intends to file a new drug application for Enhanze SC in the first quarter.
Baxter, of Deerfield, Ill., gains exclusive rights to market, distribute and sell the product in the U.S. and Puerto Rico
"We're very excited about this partnership because it represents a significant milestone for Halozyme," said Jonathan Lim, the company's chairman and CEO. "We can also mutually ...